Outlook Therapeutics OTLK is set to give its latest quarterly earnings report on Tuesday, 2022-12-27. Here's what investors need to know before the announcement.
Analysts estimate that Outlook Therapeutics will report an earnings per share (EPS) of $-0.05.
Outlook Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Outlook Therapeutics's past performance and the resulting price change:
Quarter | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
---|---|---|---|---|
EPS Estimate | -0.06 | -0.06 | ||
EPS Actual | -0.08 | -0.09 | -0.07 | -0.08 |
Price Change % | -6.5% | 7.38% | 5.26% | -0.72% |
Stock Performance
Shares of Outlook Therapeutics were trading at $0.8784 as of December 22. Over the last 52-week period, shares are down 21.32%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for Outlook Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.